GT Biopharma, Inc. (GTBP) - חוב לטווח ארוך להון

This price chart illustrates the dynamics of GT Biopharma, Inc. (GTBP), whose financial stability is currently under pressure due to high research costs, with the indicator standing at 0.00. Management is focused on advancing the TriKE system, striving for breakthrough medical outcomes. Business development relies on partnerships with global industry behemoths, which helps accelerate the commercialization of new onco-hematology therapy methods.

This metric compares liabilities with a maturity of over one year to the company's total equity, allowing for an assessment of over-leverage risk and future debt service costs. By analyzing this long-term financial stability indicator, an investor determines the degree of business autonomy. For GT Biopharma, Inc. (GTBP), a low debt load is critical when hiring expensive clinical regulatory experts, as a stable staff of immunologists requires secure funding without pressure from creditors.